You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial

 

Online download statistics by month:

Online download statistics by month: November 2020 to February 2026

AbstractFullPdf
Nov 2020276024
Dec 20202005
Jan 202172015
Feb 20213607
Mar 202191017
Apr 2021106014
May 202141020
Jun 2021005
Jul 2021007
Aug 2021009
Sep 20210016
Oct 202168031
Nov 202166024
Dec 20213805
Jan 20224009
Feb 202240012
Mar 202282012
Apr 2022132014
May 2022114012
Jun 202215809
Jul 20228408
Aug 202210008
Sep 20225805
Oct 20225005
Nov 20226606
Dec 20225403
Jan 20234005
Feb 20236004
Mar 20234406
Apr 202332011
May 202317801
Jun 202316807
Jul 2023144018
Aug 202310604
Sep 202311006
Oct 20238807
Nov 20237004
Dec 20237806
Jan 20245001
Feb 20245401
Mar 20247200
Apr 202410408
May 20249407
Jun 20249606
Jul 202417203
Aug 202411407
Sep 202410605
Oct 2024164011
Nov 2024224012
Dec 202412103
Jan 2025120011
Feb 20252201
Mar 2025005
Apr 20250047
May 2025003
Jun 2025004
Feb 2026000
Total44230516